Drug Trial Radar · NCT03275415
Intratracheal Budesonide/Surfactant Prevents BPD
Last checked: Nov 20, 2026Latest source record: May 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
310
Actual
Start
Jul 1, 2019
Primary completion
Jun 30, 2022
Study completion Jun 30, 2022
Sponsor
- Lead sponsor
- Taipei Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Taipei Medical University Hospital; National Taiwan University Hospital; Taipei Veterans General Hospital, Taiwan; Mackay Memorial Hospital; Chang Gung Memorial Hospital; China Medical University Hospital; Seventh Medical Center of PLA General Hospital; Guangzhou Women and Children's Medical Center; Taichung Veterans General Hospital
- First posted
- Sep 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 minutes, up to 4 hours
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A double-blind study includes: 1) birth Wt 500-1499 gm, 2) respiratory distress shortly after birth and requires resuscitation 3) failure to NCPAP within 4 hrs after birth, defined as: a) FIO2 ≥ 0.30, pressure \> 5cmH2O b) severe retraction c) apnea d) PCO2 ≥ 60 mmHg. Exclusion criteria: 1) lethal cardiopulmonary status 2) severe congenital anomalies. Given the COVID19 pandemics, the recruitment became difficult. Under the consideration of scientific and practical consideration, we therefore determine to have a sample of 300, (150 in each group), fulfill the criteria of type I error 0.05, type II error 0.10, power 90% and with an expectation of 30 % improvement of primary outcome (from 60 % in control group to 40 % in the intervention group as original presumed).Appropriate amount of placebo will be used as it does not affect the biophysical property of curosurf (PAS abstract 2017 San Francisco). Primary outcome of study is death or BPD defined by NICHD criteria. Follow up study of neuromotor and cognitive function and pulmonary states will be done at 1-2 years of corrected age.
Conditions
- Respiratory Distress Syndrome
- Bronchopulmonary Dysplasia
Interventions
budesonideDrug
Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
SalineDrug
Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
Primary outcomes
What the sponsor says the trial is designed to measure.
- incidence of death or BPDTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.